Loading company
Abivax S.A.
ABVX · Nasdaq · ·
$98.50+1.8%Sep 29 close
- 1M
- -13.1%
- 6M
- -3.0%
- 1Y
- +16.0%
ABVX · Nasdaq · ·
$98.50+1.8%Sep 29 close
The quarter ending December 31, 2025, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2025 | 3 months toDec 31, 2024 | Change |
|---|---|---|---|
| Profit | -$93.1M | -$44.7M | -108.14% |
| Profit per share | -$1.16 | -$0.72 | -61.90% |
| Free Cash Flow | -$26.5M | -$38.2M | +30.62% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Abivax S.A. has no earnings call transcript available.
“As we prepare Abivax for its next phase of growth and the potential commercialization of obefazimod, we are continuing to strengthen the leadership and capabilities needed to support that evolution,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K Abivax S.A. filed on September 21, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.